The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • No CSPEC computer assertion could be determined for this classification!


Variant: NM_007294.4(BRCA1):c.4186-1787_4358-1668dup

267530 (ClinVar)

Gene: BRCA1
Condition: BRCA1-related cancer predisposition
Inheritance Mode: Autosomal dominant inheritance
UUID: 9dabe68a-20a3-4a73-b261-f458820fcca3
Approved on: 2024-06-12
Published on: 2024-06-11

HGVS expressions

NM_007294.4:c.4186-1787_4358-1668dup
NM_007294.4(BRCA1):c.4186-1787_4358-1668dup

Pathogenic

Met criteria codes 2
PVS1 PM5_Strong
Not Met criteria codes 1
PM2

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen ENIGMA BRCA1 and BRCA2 Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for BRCA1 Version 1.0.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
ENIGMA BRCA1 and BRCA2 VCEP
The c.4186-1787_4358-1668dup variant in BRCA1 is a large duplication variant. This variant has been previously reported as a duplication of exon 13 (legacy exon numbering, PMID: 10827109), c.4186-?_4357+?dup (uncharacterized breakpoints), BRCA1 ~6kb dup (PMID: 9915971), c.4186-1787_4357+4122dup (PMID: 29446198) and c.4186-1832_4358-1634dup (PMID: 30054569). This duplication variant was not observed in gnomAD v2.1 (exomes only, non-cancer subset) or gnomAD v3.1 (non-cancer subset), but PM2_Supporting was not applied since recall is suboptimal for this type of variant (PM2_Supporting not met). Confirmed tandem duplication of exon 12 is predicted to cause a premature stop codon in inserted biologically-relevant-exon 12 leading to nonsense mediated decay (PVS1 met). The ENIGMA BRCA1/2 VCEP considered multiple lines of functional and clinical evidence to define exon-specific weights for PTCs in BRCA1, and results indicate that strong evidence towards pathogenicity may be applied for a PTC variant in BRCA1 exon 12 (PM5_Strong (PTC)). In summary, this variant meets the criteria to be classified as a Pathogenic variant for BRCA1-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (PVS1, PM5_Strong (PTC)).
Met criteria codes
PVS1
Confirmed tandem duplication of exon 12 is predicted to cause a premature stop codon in inserted biologically-relevant-exon 12 leading to nonsense mediated decay (PVS1 met).
PM5_Strong
The ENIGMA BRCA1/2 VCEP considered multiple lines of functional and clinical evidence to define exon-specific weights for PTCs in BRCA1, and results indicate that strong evidence towards pathogenicity may be applied for a PTC variant in BRCA1 exon 12 (PM5_Strong (PTC)).
Not Met criteria codes
PM2
This duplication variant was not observed in gnomAD v2.1 (exomes only, non-cancer subset) or gnomAD v3.1 (non-cancer subset), but PM2_Supporting was not applied since recall is suboptimal for this type of variant (PM2_Supporting not met).
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.